Research involving individuals with schizophrenia can pose unique challenges with recruitment, informed consent, clinical trial design, and the use of placebos.
The pharmaceutical industry has increasingly been adopting artificial intelligence – which has demonstrated the ability to predict instances of schizophrenia with 74% accuracy.
A proof-of-concept study using patient-derived cells to test drug response in clinical trials demonstrates the benefits of precision medicine, movement to which is the future of study design, says researcher.
Compass Pathways’ psilocybin therapy for treatment-resistant depression has received a breakthrough status to accelerate development – at a time when the incidence of mental illness is rapidly increasing.
In this first part of a two-part investigation, we look at how NDMA receptor antagonists, such as ketamine, could be poised to make a breakthrough in the treatment of depression – an area where the pharma industry has struggled to identify new targets...
